Tvardi Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Tvardi Therapeutics

08/08/2025 23:51

Tvardi Therapeutics Inc TVRD.OQ TVRD.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Tvardi Therapeutics Inc is for a loss of 57 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Tvardi Therapeutics Inc is $55.00, about 56.5% above its last closing price of $23.93

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.35
-0.35
-3.22
Missed
-820
2025
-5.04
Sep. 30 2024
-8.88
-8.28
Beat
6.8​
Jun. 30 2024
-9.64
-9.86
-13.32
Missed
-35
​​Mar. 31 2024
-14.34
-14.33
-20.16
Missed
-40.7
Dec. 31 2023
-15.70
-14.83
-21.24
Missed
-43.2​
Sep. 30 2023
-18.95
-18.72
-18.72
Met
0
Jun. 30 2023
-19.19
-19.38
-20.88
Missed
-7.7

This summary was machine generated August 8 at 22:51 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)